Lecture 9: Genetic Screening Flashcards

1. Discuss factors to consider when developing and implementing a new screening test 2. Describe and discuss prenatal screening in the clinical management of Down Syndrome and neural tube defects 3. Describe and discuss the role of screening in the clinical management of cystic fibrosis and phenylketonuria 4. Describe and discuss genetic screening strategies for adults using the example of familial hypercholesterolemia

1
Q

what are the specific issues with genetic screening based on?

A
  • Permanent results

- Implications for family members

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Explain what ACCEE is

A
  • Analytical validity – how well does the test measure what it aims to measure?
  • Does it measure what we want to measure
  • Clinical validity – how well does the test predict future health?
  • Pharmacogenetics-> used to predict response to drugs
  • Clinical utility – does the test alter health outcomes?
  • Is health outcomes affected?
  • Ethical validity – is the test ethical?
  • Collection of sample could be ethically invalid
  • Outcome of test leaves patient limited to option- e.g, can’t do abortion because forbidden by their culture = leaves only to carry on pregnancy
  • Taking multiple sample from someone who doesn’t understand what is happening-> ethical?
  • Economics – is it financially viable?
  • Cost of obtaining + analysing sample
  • E.g, cff DNA less invasive-> less use of specialist equipment for invasive testing= viable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Define true positive

A

Test positive+ has condition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Define false positive

A

Test positive+ doesn’t have condition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Define false negative

A

Test negative+ has condition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define true negative

A

Test negative+ doesn’t have condition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Define and give equation for sensitivity

A
  • Sensitivity: ability to detect the condition out of all the people who have the condition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Define and give equation for specificity

A
  • Specificity: detects someone without the condition out of all the people who do not have the condition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Define and give equation for false positive

A
  • False positive: test result is positive yet the person does not have the condition. Given as a proportion of the whole population
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Define and give equation for false negative

A
  • False negative: test result is negative yet the person does have the condition. Given as a proportion of the whole population
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Explain how who should be screened is determined

A
  • Whole population-> not economically viable for all diseases
  • Targeted populations
  • Age
  • Definition of ‘old age’
  • can be not definitive-> out + close to boundaries of age range + still be or offspring affected= DS
  • Race
  • particular disease can be viewed as ‘bad trait’ associated with race
  • E.g, sickle cell anaemia prominent with Afro-Caribbean race
  • Can become ostracised + affect employability once declared publicly
  • Family history
  • E.g, Ashkenazi Jews prone to breast cancer
  • Amish pop. is small community-> interbreeding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Explain what NICE is and their role

A
  • Provide national guidance and advice to improve health and social care
  • Make recommendations on the use of new medicines and medical technologies
  • Define healthcare pathways
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

List the factors to consider when implementing a new test

A
- ACCEE
\+ - disease incidence
- disease pathology 
- turnaround time 
- sample + analysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe what the foetal anomaly screening programme detects

A
  • Neural tube defects: anencephaly, spina bifida
  • Organ development: heart abnormalities, renal agenesis
  • Agenesis:failure of an organ to develop during embryonic growth and development
  • Skeletal dysplasia – achrondroplasia
  • Skeletal dysplasia: abnormalities of cartilage and bone growth, resulting in abnormal shape and size of the skeleton
  • Achrondroplasia: bone growth disorder that causes disproportionate dwarfism
  • Cleft lip/palate, diaphragamatic hernia, abdominal wall
  • Cleft lip/palate: gap or split in the upper lip and/or roof of the mouth
  • Diaphragamatic hernia: hole in the diaphragm-> Organs in the abdomen move through hole + upwards into a baby’s chest
  • Trisomy 18, Trisomy 13, Trisomy 21
  • T18= Edward’s syndrome
  • T13= Patau’s syndrome
  • T21= DS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Explain how foetal anomalies are screened

A
  • Biochemical analysis of maternal serum
  • Ultrasound scans, 10-14- and 18-21-weeks gestation
     10-14= done for mum to identify gestational diabetes + HIV that can be passed onto offspring + dating scan (how far long)
     18-21= done for detecting foetal anomalies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Explain and compare the advantages of ultrasound

A

Advantages:

  • non-invasive
  • no known risk to mother or feotus
  • relatively cheap to perform

Disadvantages:

  • expensive equipment
  • skilled & experienced personnel
  • fetal position-> Position makes it unable to see anomalies
  • maternal BMI-> more of ultrasound absorbed by subcutaneous fat rather than pass through and reflected for image to be formed
17
Q

Describe what the newborn blood spot is and what it is used for

A
  • Heel pricked of new born-> collect blood sample on Guthrie card
  • Used to detect inherited metabolic diseases
18
Q

List the inherited metabolic diseases it can identify

A
Phenylketonuria (PKU)
•Medium chain acyl-CoA
dehydrogenase deficiency
(MCADD)
•Maple syrup urine disease
(MSUD)
•Isovaleric acidaemia (IVA)
•Glutaric aciduria type 1
(GA1)
•Homocystinuria (HCU) 
• Sickle cell disease
• Cystic fibrosis
• Congenital hypothyroidism
19
Q

Explain the pathophysiology for PKU

A
  • Gene for phenylalanine hydroxylase mutated= abnormal protein -> doesn’t convert phenylalanine to tyrosine
  • Increase + build-up of phe and decrease of tyr
  • Build-up -> causes phe to convert to phenylketones
  • Decrease in tyr-> causes depletion of neurotransmitters + melanin
20
Q

State when neonatal screening for PKU is done and why at this time

A

5 days old-> allow metabolite to accumulate

21
Q

Describe the clinical features of PKU

A
  • Blond hair, blue eyes-> due to lack of melanin
  • Intellectual impairment-> due to lack of neurotransmitters
  • Seizures-> due to lack of neurotransmitters
22
Q

Explain how PKU can be treated

A
  • Very effective + easy: Severely restrict dietary intake of phenylalanine (low protein diet)
  • Phenylalanine - an essential amino acid= can’t be produced by body-> has be sourced externally by diet
  • PKU present for 1st 20yrs of life
  • After approx.20yr-> relax diet in adulthood + except pregnancy
23
Q

Name the disease that is identified using adult screening

A

Familial hypercholesterolemia (FH)

24
Q

State the mode of inheritance for FH

A
  • Autosomal dominant
25
Q

State how FH is characterised

A
  • Characterised by high LDL-cholesterol: 200-400 mg/dL (N: 75-175 mg/dL)
26
Q

State what FH can lead to

A
  • Causes and leads to premature coronary artery disease, myocardial infarctions & death
27
Q

State what can see around the tendons of people with FH

A
  • Tendon xanthoma= deposits of LDL cholesterol
28
Q

Explain the pathophysiology & treatment for FH

A
  • Sources of LDL cholesterol: Diet (external) + Synthesis(internal)
  • LDL-cholesterol taken up by LDL-Receptor
  • Feedback mechanism maintains LDL levels in blood
  • LDL-R is defective in FH patients
  • Treatment: statins inhibit cholesterol synthesis
29
Q

Evaluate FH pop. screening

A
  • Good idea:
  • Common condition
  • Serious health implications
  • Effective treatment
  • Increase in life expectancy-> more conscious of diet
  • However:
  • LDL-cholesterol levels not sufficiently specific or informative in younger patients
  • > can have high LDL and not have FH
  • Genetic testing is expensive and complicated-> 18 exons
30
Q

Explain what casade screening is

A
  • Test affected + test relatives
  • If relative pos. -> test family of that relative
  • Keep continuing to identify individuals who are affected + do not know
31
Q

Evaluate cascade screening

A

Advantages:

  • Application of diagnostic test to those individuals at most risk of having the disease.
  • Cost-effective

Disadvantages:

  • Time consuming-> have to get in contact with family + relatives + obtain from each a sample
  • Delay in diagnosis, delays treatment
32
Q

Explain how trivialities of cascade screening

A
  • Have to consider how to deliver news to relatives that they could have disease-> inform by using leaflets + advise for testing